On Tuesday, August 4, before market open, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported its second-quarter 2015 financial results that beat both top and bottom line expectations. The biotech giant, which recently …
Investors are patiently awaiting the results of XOMA Corp’s (NASDAQ:XOMA) EYEGUARD B Phase III trial. Shares of the company last closed at $4.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) excited Wall Street on July 2 after the company announced that the U.S.
In a research report issued today, Piper Jaffray analyst Edward Tenthoff weighed in with a few insights on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) following Avalanche’s …
On May 19, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced plans to complete a New Drug Application (NDA) for eteplirsen, Sarepta’s lead product candidate. SRPT …